Efficacy

Proven efficacy in patients who have had prior TKI therapy1
BOSULIF was studied in a single-arm, Phase 1/2, open-label, multicenter trial in 546 patients with CML
  • Patients included adults with CP, AP, and BP CML who developed resistance or intolerance to 1st-line imatinib, or 1st-line imatinib then dasatinib and/or nilotinib
The efficacy and safety of BOSULIF as 2nd- and 3rd-line treatment were evaluated in a long-term follow-up of patients with resistance or intolerance to prior therapy
  • The long-term analysis was based on a minimum of 60 months of follow-up for patients with CP CML treated with one prior TKI (imatinib) and a minimum of 48 months of follow-up for patients with CP CML treated with imatinib and at least one additional TKI (nilotinib and/or dasatinib)
BOSULIF helped patients achieve MCyR after treatment with imatinib (n=262 evaluable)1,a

Median duration of MCyR was not reached at the time of analysis1
62% (n=96) of patients who achieved MCyR at any time (n=156) stayed on BOSULIF for at least 5 years2
BOSULIF helped patients achieve MCyR after treatment with imatinib followed by dasatinib or nilotinib (n=112 evaluable)1,b

Median duration of MCyR was not reached at the time of analysis1
Treatment with BOSULIF helps patients remain in chronic phase1
  • 95% of patients remained in CPc while taking BOSULIF (n=383 out of 403)
    — 5% of patients in CP had confirmed disease transformation to AP or BP while taking BOSULIF (n=20 out of 403)
Proven hematologic response rates with BOSULIF (n=132 evaluable)1
Hematologic responses in AP CML by 48 weeks

Hematologic responses in BP CML by 48 weeks

  • Patients were treated with BOSULIF 500 mg once daily
  • Of the 546 treated patients, 506 were considered evaluable for efficacy. Patients were evaluable for efficacy if they had received at least 1 dose of BOSULIF and had a valid baseline efficacy assessment

References
  1. BOSULIF Prescribing Information. New York, NY: Pfizer Inc.
  2. Data on file. Pfizer Inc, New York, NY.